Novo Nordisk
ENTRAAWorld leader in diabetes and obesity drugs, rebuilding R&D around data science and AI.
novonordisk.com145 open roles at Novo Nordisk
Verified live postings · updated JUL 11, 2026
Get notified when Novo Nordisk posts a new role
Free · email when published · no weekly noise
Hiring quality verdict.
Novo Nordisk has moved from pure drug discovery to data-driven drug development at scale: its AI and data science function spans Copenhagen, Oxford, and Boston, building molecular design models and patient-stratification tools for its GLP-1 compound portfolio. The Novo Nordisk Foundation anchors Denmark's first AI supercomputer (Gefion) and an enterprise OpenAI agreement deploys GPT-based tools across R&D workflows. With Ozempic and Wegovy still in high-demand growth, hiring is weighted toward bioinformatics engineers and MLOps specialists who can translate model outputs into regulatory-grade evidence packages.
Novo Nordisk by the numbers.
145
Verified live postings
+45%
Net-new AI hires (12-month)
Public · NOVO.CO · NYSE:NVO (ADR)
Pharmaceuticals · Life Sciences AI
Verified salary ranges.
Total comp · USD · annual
Who runs talent at Novo Nordisk.
Maziar Mike Doustdar
CEO (from August 2025)
Karsten Munk Knudsen
CFO
Novo Nordisk in ENTRA Intelligence.
Copenhagen's Pay Transparency Edge in the EU AI Race
Denmark's tradition of wage openness has made Copenhagen one of Europe's most transparent AI talent markets—and the EU Pay Transparency Directive will only deepen the advantage.
Nordic AI Pay Transparency: Inside Sweden, Norway and Denmark's Disclosure Lead
82% of Nordic AI postings carry salary ranges in August 2026, more than double the EU pre-directive mean, as Sweden, Norway, and Denmark lead on pay disclosure.
Remote Issue Week 3: What 28 Cities Reveal About AI Hiring
At 28 cities, four new forces are visible: clearance comp floors, Nordic welfare dividends, university corridor clustering, and satellite hub arbitrage.
Novo Nordisk vs. peers.
More coverage
Browse all companies in our editorial coverage.